Skip to main content

Milestone 5.C

Initiate phase III drug trials for agents against at least 3 currently known therapeutic targets. Of these, at least one trial will be asymptomatic, at risk populations. These trials will incorporate a combination of biomarkers (fluid and imaging) and cognitive measures as outcomes and include collection of DNA and other bio-samples for interrogation of responsiveness. 


Success Criteria

  • Comprehensive success/failure analysis of data from at least 3 phase III trials.


Research Implementation Area
Drug Development - Existing Targets
Timeline
2017–2023
Status
In Progress

Implementation Activities

Funding Initiatives

Research Programs and Resources

Relevant Recommendations